<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260711070122N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-07-25</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Ketamine on Sleep Quality After AbdominalSurgery</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of Low-Dose Ketamine on Sleep Quality During the Early Postoperative Days After Major Abdominal Surgery: A Randomized, Double-Blind Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-08-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/91704</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Simple randomization: In this study, the unit of randomization will be the individual patient. After assessment of eligibility criteria and written informed consent, eligible patients will be allocated in a 1:1 ratio to either the ketamine or placebo group. Simple randomization will be used, and no stratified or cluster randomization will be performed.
Before participant recruitment begins, the random allocation sequence will be generated using computer-generated random numbers by an independent individual who will have no role in participant recruitment, intervention delivery, outcome assessment, or data analysis. According to this sequence, each participant enrolled consecutively will be assigned to one of two groups: ketamine or placebo.
To ensure allocation concealment, the master randomization list will be accessible only to the independent pharmacist or nurse responsible for preparing the study medication. The investigator responsible for assessing eligibility and enrolling participants will not have access to the allocation sequence. After eligibility has been confirmed and written informed consent obtained, the next sequential study number will be assigned to the participant, and the independent individual will prepare the study medication corresponding to that number.
Ketamine and placebo will be prepared in identical syringes or infusion pumps, with identical appearance, volume, and labeling. Participants, surgeons, anesthesiologists, intensive care unit nurses, outcome assessors, and the data analyst will remain unaware of treatment allocation until data collection and analysis are complete, Blinding description: This is a randomized, double-blind, placebo-controlled clinical trial. Participants, healthcare providers, outcome assessors, and the data analyst will be blinded to group allocation. Patients will be randomly assigned in a 1:1 ratio to ketamine or placebo using a computer-generated sequence. The study drugs will be prepared by an independent pharmacist or nurse and will be identical in appearance, volume, and labeling.</study_design>
      <phase>3</phase>
      <hc_freetext>Early postoperative sleep disturbance in patients undergoing major abdominal surgery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Following induction of general anesthesia, patients will receive an intravenous bolus of ketamine at 0.25 mg/kg body weight, followed by a continuous intravenous infusion of ketamine at 0.1 mg/kg/h until skin closure. Ketamine administration will be limited to the intraoperative period and will not be continued after surgery. Other anesthetic care and postoperative pain management will be provided according to the center’s standard protocol. Intervention 2: Control group: Following induction of general anesthesia, patients will receive an intravenous bolus of normal saline, followed by a continuous infusion of normal saline at an equivalent volume and rate until skin closure. Placebo administration will be limited to the intraoperative period and will not be continued after surgery. Other anesthetic care and postoperative pain management will be provided in accordance with the center’s standard protocols.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Deidentified individual participant data will not be shared because no formal data-sharing plan has been established, and access to study data will be restricted to authorized members of the research team to protect participant confidentiality.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Negar Namazi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Anesthesiology Research Center, Ayatollah Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1985914674</zip>
        <telephone>0098196306603</telephone>
        <email>negar.namazi99@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Negarsadat Namazi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Anesthesiology Research Center, Ayatollah Taleghani Hospital,Tehran, Iran.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1985914674</zip>
        <telephone>0098196306603</telephone>
        <email>negar.namazi99@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age range: 18–80 years
Patients with ASA physical status I–III
Candidates for elective major abdominal surgery
Extubation at the end of surgery or within the first postoperative hours
Ability to comprehend and complete the sleep and pain questionnaires
Written informed consent</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>85 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Minor surgery, such as uncomplicated cholecystectomy
Expected need for mechanical ventilation beyond the first postoperative night
Preoperative hepatic encephalopathy
Severe renal failure
Severe psychiatric illness, active psychosis, or hallucinations
Severe preoperative insomnia (Athens Insomnia Scale [AIS] score ≥ 6)
Chronic ketamine use
Substance abuse
Declining to participate in the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G47</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Sleep disorders</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Following induction of general anesthesia, patients will receive an intravenous bolus of ketamine at 0.25 mg/kg body weight, followed by a continuous intravenous infusion of ketamine at 0.1 mg/kg/h until skin closure. Ketamine administration will be limited to the intraoperative period and will not be continued after surgery. Other anesthetic care and postoperative pain management will be provided according to the center’s standard protocol</i_keyword>
      <i_keyword>Control group: Following induction of general anesthesia, patients will receive an intravenous bolus of normal saline, followed by a continuous infusion of normal saline at an equivalent volume and rate until skin closure. Placebo administration will be limited to the intraoperative period and will not be continued after surgery. Other anesthetic care and postoperative pain management will be provided in accordance with the center’s standard protocols.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The incidence of postoperative sleep disturbance on the first postoperative day. Postoperative sleep disturbance is defined as an Athens Insomnia Scale (AIS) score of 6 or higher or a Sleep Numerical Rating Scale (Sleep NRS) score of 6 or lower. Patients meeting at least one of these criteria will be considered to have postoperative sleep disturbance. Timepoint: after the first and third postoperative nights. Method of measurement: Measurement will be performed using the Athens Insomnia Scale and the Sleep Numerical Rating Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Postoperative pain intensity at rest and during coughing or movement, measured using the Visual Analog Scale. A score of 0 indicates no pain, and a score of 10 indicates the worst imaginable pain. Timepoint: On postoperative days 1 and 3, after the first and third postoperative nights. Method of measurement: Postoperative pain intensity at rest and during coughing or movement, measured using the Visual Analog Scale. A score of 0 indicates no pain, and a score of 10 indicates the worst imaginable pain.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name>Shahid Beheshti University of Medical Sciences</sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
      <source_name>Anesthesiology Research Center, Taleghani Hospital</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-07-19</approval_date>
        <contact_name>Ethics Committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Velenjak - Moghaddas Ardebili St. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
